53%) of the combination group and in four patients (23 53%) of th

53%) of the combination group and in four patients (23.53%) of the chemotherapy group. No significant difference was found between the two groups (23.53% see more vs 23.53%; P > 0.05). No serious adverse events were observed ( Table 3). The results of our study suggest that CT-PFNECII combined with second-line chemotherapy produced a higher response rate and improved survival than second-line chemotherapy in platinum-pretreated stage IV NSCLC. In addition, side effects of this combination

therapy were generally well tolerated. Compared with ORR of 11.76% and DCR of 35.29% in the chemotherapy group, the combination therapy provided an ORR of 23.53% and a DCR of 58.82% in platinum-pretreated stage IV NSCLC. Of note, one complete tumor regression was achieved in a patient by two cycles of combination treatment. More importantly, all patients who had lung tumor–related chest pain or dyspnea before our treatment achieved significant symptom relief even within 72 hours after CT-PFNECII treatment. Our pilot

study suggests that CT-PFNECII combined with second-line Gemcitabine purchase chemotherapy has potent antitumor activity against platinum-pretreated NSCLC tumors. The benefit of our combination treatment in terms of survival outcomes was also quite encouraging. Considering that 29.41% of patients in our study population were platinum resistant (five patients in each arm) and 58.82% of the patients (10 of 17) received CT-PFNECII two times, the PFS of 5.4 months and OS of 9.5 months by our combination treatment were more valuable. The side effects of CT-PFNECII such as transient mild pain and cough in patients with lung cancer were minimal and well tolerated because only quite small amount of cisplatin and quite low concentration of ethanol were injected intratumorally. In addition, mild pneumothorax PIK3C2G and mild hemoptysis relating to the procedure were uncommon because we used a 22-gauge fine needle under the precise guidance of CT. Furthermore, combination of CT-PFNECII with second-line chemotherapy did not worsen common side effects of chemotherapy. No significant differences in chemotherapy-related adverse events in the two groups

were noted, indicating clinical safety of CT-PFNECII. We previously found that 5% ethanol could potently inhibit ABCG2 pump, which is a major drug transporter in protecting platinum-resistant NSCLC cells from cytotoxic agents. We also found that 5% ethanol-cisplatin injected intratumorally could eradicate cisplatin-resistant lung tumors by killing chemoresistant lung CSCs and normal lung cancer cells [10]. We speculate that the residual unkilled but damaged tumor cells in the 5% ethanol-cisplatin treatment group might be more fragile and sensitive to second-line chemotherapy agents. As a result, we speculate that CT-PFNECII treatment might have synergistic effects with systemic second-line chemotherapies, such as docetaxel or pemetrexed, in controlling platinum-pretreated NSCLC.

Posted in Uncategorized | Leave a comment

Statistical analysis was performed using Prism software (La Jolla

Statistical analysis was performed using Prism software (La Jolla, CA, USA). The Harboe method has been established for determining hemoglobin concentrations in solution using spectrophotometric measurement at 415 nm and has been validated for assessing hemolysis in red cell

samples [14] and [15]. We adapted this method for estimating erythroid cell concentrations in unlysed culture samples and determining erythroid proliferation in a non-invasive manner. Hemoglobin shows maximum light absorption between 400 and 420 nm and we found absorbance at 405 nm and 415 nm to correlate linearly (R2 = 0.9999) allowing the use of 405 nm absorbance filters commonly available on standard plate readers ( Fig. 1a). We established that the lysis of erythrocytes is not necessary for reliable hemoglobin quantification buy VX-770 and that cell suspensions could be directly subjected to spectrophotometric measurement ( Fig. 1b, R2 = 0.9905). Initial assay set-up was performed using samples of native erythrocytes isolated from donor blood suspended in PBS and absorbance measurements at 405 nm were found to correlate linearly

(R2 = 0.998) with manual cell counts ( Fig. 1c). Using the function obtained from the linear fit of such an erythrocyte standard curve using GraphPad software, cultures could be expressed MS-275 supplier as ‘erythrocyte equivalents’ based on their absorbance (erythrocyte equivalents/ml = (5,413,000 ± 91,210) × A405 − (154,700 ± 80,730)). Absorbance measurements were obtained from in vitro erythroid cultures at various time points of culture using a plate reader pre-heated to 37 °C, and plates were agitated to disperse cells evenly in the microwells before measurement. The absorbance values were corrected using the absorbance of the medium of each condition and normalized to a positive control culture on the same plate to determine the hemoglobinization as percentage of the positive control that in turn correlated with the cell expansion (Fig. 2). Hemoglobinization begins at the proerythroblast stage and two thirds

of a cell’s total hemoglobin are produced by the erythroblast while the remaining third is synthesized at the reticulocyte stage Abiraterone cost [35]. In culture, cells contained detectable amounts of hemoglobin from day 8 after seeding into erythroid medium, showed strong increase in hemoglobinization over the next 7 days and reached a plateau thereafter. Absorbance measurements based on hemoglobin remained stable over extended periods of time showing only slight decreases in absorbance after further 10 days (Fig. 3), indicating that this molecule is not readily degraded even when it is released into the culture supernatant upon cell death and rupture. Cell concentrations and absorbance measurements for erythroid cultures correlated linearly and while standard deviations were larger than for native red blood cell samples, these varied comparably for both measurement principles due to higher biological variation between triplicate wells.

Posted in Uncategorized | Leave a comment

Although it is unknown whether anemia itself causes the extensive

Although it is unknown whether anemia itself causes the extensive morbidity or mortality seen in older anemic adults, it is plausible to see more suggest that anemia, potentially leading to local

tissue hypoxia, could aggravate functional decline and, furthermore, that treatment of anemia has the potential to ameliorate some, if not all, of these significant negative effects. This trial involved performing a comprehensive battery of physical, cognitive, quality of life, and frailty tests. Although the findings were modest, this study shows that it is feasible to perform comprehensive evaluations in this population. Such investigation could form the basis for future studies in older anemic adults to better ascertain the exact benefits across relevant domains of physical function, cognition, quality of life, and frailty. Future trials focusing on treatment of UAE should utilize streamlined, patient-friendly design, minimal entry criteria, and intensive recruitment efforts tailored toward older Sorafenib solubility dmso adults. It will also be critical for future studies of UAE to significantly expand the patient recruitment base by increasing the numbers of participating institutions. None of the authors had any financial, personal, or other interest in this work or perceived conflict of interest. The PACTTE Steering Committee designed the study. HB and SS analyzed the data. EP, ASA, HB, SS, GC, SLS, and HJC prepared the manuscript. All authors critically revised

the manuscript and approved the final version. The principal investigators have full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors thank Thymidylate synthase Kerstin McHutchinson, Carrie Elliott, Kimberly Hickman, Joselene Sipin-Sayno, Ora White, Karina Ramirez, Mat Nelson, Nyesha Smith, Lisa Pape, Irene Flores, and Lani Krauz. This work was funded by the National Institutes of Health (NIH) Grant 5U01AG034661. IVIS was provided by Luitpold Pharmaceuticals. Neither

the NIH nor Luitpold was involved in the study design; collection, analysis and interpretation of data; writing of the report; or the decision to submit the article for publication. “
“Hepcidin is a cysteine-rich peptide hormone that regulates the absorption and distribution of iron in humans and other animals [1]. Hepcidin production is transcriptionally regulated in the liver in response to body iron stores and inflammation [2]. Increases in plasma iron levels result in enhanced signaling via bone morphogenic proteins [3] and phosphorylation of Smad1,5, and 8, which facilitates Smad4 binding to the Hepcidin promoter and greater Hepcidin transcription [4]. The inflammatory cytokine, interleukin-6, IL-6, can also upregulate Hepcidin by activating Stat3 and enhancing Stat3 binding to the Hepcidin promoter [5]. Hepcidin binds ferroportin1, the only known vertebrate iron exporter, resulting in internalization and degradation of both proteins [6].

Posted in Uncategorized | Leave a comment

1 41 18 ± 3 25* pmol/mL) but, only for the higher concentration a

1 41.18 ± 3.25* pmol/mL) but, only for the higher concentration at 90 min (Cont. 10.81 ± 0.54; TsNP0.1 46.67 ± 1.60* pmol/mL) and 120 min (Cont. 9.84 ± 1.39; TsNP0.1 68.00 ± 7.60* pmol/mL). mRNA expression of the natriuretic peptide receptor-A, -B, -C, and of the guanylate cyclase-C genes was analyzed in the perfused kidneys because cGMP concentrations were elevated in the urine samples. NPR-A mRNA expression was down regulated in the kidneys treated with both concentrations of TsNP (0.03 and 0.1 μg/mL). In contrast,

the NPR-B, NPR-C and CG-C genes showed an up regulation following 0.1 μg/mL treatment (Fig. 5). As the expression of all of the genes was affected and because Linsitinib the NPR-C receptor does not act via cGMP as a second messenger, we decided to analyze other genes involved in NPR-C signal transduction. Therefore, we analyzed the mRNA levels of eNOS, MAPK-1 and TGFβ-1. A down regulation of eNOS mRNA was observed for both TsNP concentrations (Control 1.046 ± 0.082; TsNP0.03 0.156 ± 0.046*; TsNP0.1 0.276 ± 0.083* relative expression rate). However, an up regulation of TGFβ-1

mRNA was found for 0.1 μg/mL TsNP concentration (Control 1.124 ± 0.345; TsNP0.03 2.751 ± 0.969*; TsNP0.1 4.459 ± 1.020* relative expression rate). MAPK-1 gene expression was not affected by the TsNP treatment. Natriuretic peptides have been extensively investigated due to their potential for the treatment of cardiovascular diseases such as congestive heart failure. Despite all the advances that have been made in this field, only two NP-based drugs have been produced. Unfortunately, both of these Crenolanib order drugs possess poor pharmacokinetic properties and have adverse effects that limit their use (Vink et al., 2010). Since the discovery of venom-related natriuretic peptides, first in snakes, then in platypus, a number of chimeric peptides have been produced. These have resulted in peptides with greater stabilities and new pharmacological properties. These peptides have shown advantages over their mammalian counterparts for therapeutic use (Lisy et al., 2008 and Vink et al., 2010). In platypus and snake venoms,

from natriuretic peptides are encoded in the same gene regions of bradykinin-potentiating peptides (BPP) or metalloprotease-inhibiting peptides and are posttranslationally liberated (Fry et al., 2009). This is the first report of the isolation of a natriuretic peptide from scorpion venom. Sequence alignment of TsNP shows a structural similarity to C-type natriuretic peptides. Recently, a family of peptides was isolated from T. serrulatus venom. These peptides shared a sequence signature with the bradykinin-potentiating peptides (BPP) found in snake venom ( Verano-Braga et al., 2008). Higuchi et al. (1999) showed that BPP and C-type natriuretic peptide are encoded by the same genes in species of the Crotalinae subfamily.

Posted in Uncategorized | Leave a comment

042) Cortical perimeter increased significantly from baseline in

042). Cortical perimeter increased significantly from baseline in both the ELD group (2.63 ± 7.52%, p = 0.008) and the ALF group (3.86 ± 6.28%, p < 0.001). Thus, although there was no significant difference between the effects of the two drugs on the increased cortical perimeter, ELD prevented the decrease in cortical thickness. Cortical vBMD of the femoral neck increased

significantly in both the ELD group (1.82 ± 4.78%, p = 0.004) and the ALF group (2.21 ± 4.98%, p < 0.001), with no difference between the two groups ( Fig. 1). Trabecular vBMD of the femoral neck significantly decreased in both the ALF group (− 7.49 ± 8.82%, p < 0.001) and the ELD group (− 3.99 ± 7.83%, p < 0.001), and there was a significant difference between the two groups (p = 0.020). Total vBMD NVP-BGJ398 purchase of the femoral neck decreased from baseline in the ALF group (− 2.25 ± 5.32%, p < 0.001), whereas it was maintained in the ELD group. Accordingly, the percentage changes in total vBMD differed significantly between the ELD and ALF groups (p = 0.009). Regarding cortical CSA, the ELD group showed a non-significant trend for an increase (1.73 ± 7.62%,

p = 0.082) and the ALF group showed a non-significant trend for a decrease (− 0.96 ± 6.14%, p = 0.212) ( Fig. 1). Thus, the percentage changes from the baseline in cortical CSA showed a significant difference between the ELD and ALF groups (p = 0.031). Trabecular CSA of the femoral Calpain neck increased significantly in the ALF group (2.92 ± 7.74, p = 0.003), but not in the ELD group (1.92 ± 7.61%, p = 0.054). Total CSA increased from the baseline in both the buy Cobimetinib ELD group (1.69 ± 6.78%, p = 0.056) and the ALF group (1.51 ± 5.77%, p = 0.039), with no difference between the two groups. Cortical bone mass of the femoral neck increased significantly from baseline in both the ELD group (3.68 ± 7.51%, p < 0.001) and the ALF group (2.45 ± 9.64%, p = 0.045) ( Fig. 1). Total bone mass of the

femoral neck increased significantly only in the ELD group (1.93 ± 5.89, p = 0.013). Trabecular bone mass significantly decreased in the ALF group (− 3.96 ± 9.39, p < 0.001), whereas it did not change from baseline in the ELD group, and there was no significant difference between the two groups (p = 0.268). Thus, in the ELD group, both total and cortical bone mass increased from baseline, and trabecular bone mass was maintained. Biomechanical properties (CSMI, SM, and BR) of the femoral neck were compared between the ELD group and the ALF group (Fig. 2). CSMI and SM improved significantly in the ELD group (5.30 ± 11.56%, p < 0.001 for CSMI; 4.33 ± 11.92%, p = 0.006 for SM), whereas these parameters did not change in the ALF group. Thus, there were significant differences between the ELD and ALF groups in the percentage changes of CSMI and SM from baseline (p = 0.037 and p = 0.023, respectively).

Posted in Uncategorized | Leave a comment

To assess quantitative concordance of the signal magnitudes of ea

To assess quantitative concordance of the signal magnitudes of each assay, a linear regression was performed as

shown in Fig. 3B. An R2 value of 0.9 was obtained in this case with one clear outlier which yielded an abnormally high signal in the VeraCode™ assay. Eliminating this outlier yields an R2 value of 0.96. Next, in order to assay these two distinct biomarker types (autoantibodies to TAAs and non-antibody serum proteins) in multiplex, we formatted a novel hybrid assay on the VeraCode™ platform. p53 TAA beads for autoantibody detection were configured as before. For detection of the non-antibody serum proteins, the beads were configured for a sandwich immunoassay by attaching capture antibodies for CEA and GDF15 on different barcoded

bead species. Following incubation of the pooled beads with the serum/plasma samples (to capture either anti-p53 see more autoantibody, CEA or GDF15), detection of bound autoantibody was with a fluorescently labeled monoclonal mouse anti-[human IgG] secondary antibody, which was chosen for its lack of cross-reactivity with mouse IgG (i.e. the CEA and GDF15 capture and detection antibodies). Detection of the bound CEA and GDF15 proteins was with corresponding biotin labeled detection antibodies followed by a fluorescently labeled streptavidin. Importantly, owing to the unique 2-color fluorescent readout capabilities of the BeadXpress™ reader, autoantibody detection and CEA/GDF15 detection could be achieved with different colors (DyLight™ 649 at 670 nm Staurosporine emissions and R-Phycoerythrin at 578 nm emissions, respectively). This adds an extra measure of assurance that if any cross-reaction between the autoantibody and sandwich immunoassay systems were to occur, it would not generate a signal (e.g. if the anti-[human IgG] were to cross-react with the CEA or GDF15 beads, this could be distinguished from true CEA or GDF15 Rapamycin price signal on the basis of the fluorescence color). Nonetheless, a critical first step was to confirm that these three biomarkers could indeed be multiplexed without cross-reaction or interference among the various

capture and detection agents. As a first step, since recombinant protein standards are available for CEA and GDF15, the standards were spiked into BSA Block buffer (see Materials and methods) to create high and low positive samples in the VeraCode™ assay. A series of single-plex measurements were performed to test all possible permutations of capture antibody bead species, analyte (CEA or GDF15) and detection antibody. Results are shown in Fig. 4A. As seen, a positive, dose dependent signal was only observed in cases where the correct capture and detection antibodies were matched with the correct analyte, and no signal when mismatched (the blank, corresponding to buffer without analyte, also yielded no signal).

Posted in Uncategorized | Leave a comment

They received a control/experiment diet and drinking water ad lib

They received a control/experiment diet and drinking water ad libitum during the experimental period. Two different sets of experiments (1 and 2) were conducted at different times. Initially, corn oil (0.1 ml, V group) or B(a)P (1 mg in 0.1 ml corn oil, BP group) was administered by gavage to all animals that were maintained on standard laboratory diet (Fig. 1). After 24 h of corn oil or B(a)P administration, mice were randomized into seven subgroups. One of the subgroups (from both the groups V and BP)

was killed at 24 h time point [subgroups V(+24h) and BP(+24h)] click here whereas half of the 6 subgroups (from both the groups) were continued on the powdered control diet (standard laboratory diet) and the other half were shifted to powdered experimental diet (0.05% curcumin in standard laboratory diet), which was prepared as described [11]. In experiment 1, mice shifted to control/experimental diets were killed after 24, 72 and 120 h [BP(+48h), BP(+96h), BP(+144h) (control diet)/BP(+48h) + C 24 h, BP(+96h) + C 72 h, BP(+144h) + C 120 h (experimental diet)] whereas in experiment 2, they were killed after 7, 14 and 28 days

[BP(+8d), BP(+15d), BP(+29d) (control diet)/BP(+8d) + C 7d, BP(+15d) + C 14d, BP(+29d) + C 28d (experimental diet)]. Both the experiments 1 and 2 had independent V(+24h) and BP(+24h) groups. Animals in all subgroups were observed for any apparent signs of toxicity such as weight loss or mortality during the entire study period. Animals were killed by CO2 asphyxiation and their liver and lungs were perfused and excised, and a part of the liver and lungs tissue were fixed in 10% Buparlisib manufacturer buffered formalin for histopathological evaluation and immunohistochemical (IHC) staining, while the rest of the tissues were snap frozen in liquid nitrogen and stored at -80 °C until preparation of extract. The experimental conditions, i.e. dose, route of B(a)P administration, sampling time, dose and route of curcumin exposure employed in the present

study, were chosen on the basis of our earlier studies demonstrating the effect of curcumin on the formation of BPDE-DNA adducts in mouse liver and lungs ([7] and [12]). Total cell lysates from the tissues were Molecular motor prepared by previously described cell fractionation procedure [13]. The lysates were aliquoted, their protein content was determined, and they were stored at -80 °C. The total cell proteins (50–100 μg) were resolved on 8–12% sodium-dodecylsulphate polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane. After blocking with 5% non-fat skimmed milk in Tris-buffered saline (TBS, pH 7.4) containing 0.1% Tween-20 (TBST), the membranes were probed with antibodies for Bax, Bcl-2, caspase-3, PCNA, cyclin D1 overnight at 4 °C. All primary and secondary antibodies were first standardized for their dilution and then used accordingly.

Posted in Uncategorized | Leave a comment

Two patients underwent a diagnostic ER during the treatment proto

Two patients underwent a diagnostic ER during the treatment protocol of slightly elevated BE islands in order to avoid having RFA performed on possibly invading cancers (thus not to supplement the efficacy of RFA). Histology of both ER specimens showed only LGIN. No fatal or severe complications occurred. Four patients (15% [95% CI, 4%-35%]) developed complications after ER or RFA, which were graded as moderate. One patient developed delayed bleeding 6 days after ER. This patient received blood transfusion and was treated successfully with endoscopic hemostatic

therapy (adrenaline injection, bipolar probe coagulation, and clip placement). Two patients had unplanned admissions: one patient was admitted for observation after a superficial laceration that showed no transmural leakage on the swallowing contrast examination. However, Selleck Ulixertinib this LY2109761 order 80-year-old patient became delirious and, as a result, the admission was prolonged; another patient was admitted 3 days after the RFA procedure because of pain, nausea, and vomiting that resolved with conservative treatment. Because both admissions were for >4 days, these complications were graded as moderate. The fourth patient with a moderate complication had a relative stenosis after ER and developed symptoms of dysphagia after RFA, which resolved

after two dilatations. In 7 patients (27% [95% CI, 12%-48%]), a superficial laceration was observed during the circumferential ablation procedure. Six of these superficial lacerations remained asymptomatic, did not require intervention, and were therefore not considered to be complications. However, one patient was admitted for observation (see

previously), because this was the first laceration we observed during our RFA experience. This patient, again, did not experience symptoms attributable to the laceration. Lacerations were located either at the level of the reflux stenosis (n = 4) or at the level of the ER scar (n = 3). In 4 of the 7 patients, the laceration was noted after the first circumferential ablation pass, and the second pass was either therefore not performed (n = 1) or was modified by the use of a balloon with a smaller NADPH-cytochrome-c2 reductase diameter (n = 1) or by skipping the zone containing the laceration during the second RFA pass (n = 2). All patients were able to continue the RFA according to the protocol 2 to 3 months later. Patients who achieved CR-neoplasia and CR-IM were followed-up for a mean (± SD) duration of 29 ± 9.1 months (21 ± 11.7 months since last treatment session). None of the 20 patients developed neoplasia during follow-up, thus 100% (95% CI, 82%-100%) continued to have CR-neoplasia status. Two patients had small islands of BE during follow-up.

Posted in Uncategorized | Leave a comment

Exclusion criteria were as follows: diabetes mellitus determined

Exclusion criteria were as follows: diabetes mellitus determined by either self reported histories or evidence within the hospital case notes; primary lung disease including chronic obstructive pulmonary disease; musculoskeletal Dolutegravir purchase diseases; uncontrolled hypertension of more than 170/110 mmHg; myocardial infarction or

unstable angina within previous 3 months; acute or chronic infection, inflammatory diseases such as sepsis, arthritis or systemic connective tissue disease; symptomatic peripheral vascular disease; alcohol abuse; serum creatinine 200 mmol/l; valvular cardiomyopathy or artificial heart valve; malignant disease, significant liver, thyroid, suprarenal gland or pituitary disease; cardiac cachexia defined as unintentional weight loss of 7.5% body weight over 6 months [8]. Finally, we included 71 patients because 3 patients were characterised by occlusion of internal carotid artery, while vertebral artery was not visualised in 2 patients. The control group consisted of 20 healthy male volunteers aged 55 years and above, selleck products who did not take medications. No previous medical illness was reported (including diabetes or any other cardiovascular disease). After the patient gave his written consent, the medical history was reviewed, including the

cause of heart failure, comorbidities and medical history. Each patient with CHF was categorised Pyruvate dehydrogenase according to the New York Heart Association (NYHA) criteria [9]. A physical exam was performed to assess CHF stability. The 6-min walk test was performed according to the standard protocol [10]. All patients underwent a two-dimensional Doppler echocardiography examination (GE Vivid 7). Systolic function was quantified by measurement of LVEF using the Simpson method.

We also measured left ventricular end-diastolic diameter (LVEDD), right ventricular systolic pressure (RVSP) and left atrial volume (LAV) according to the ASE recommendation [11]. During an initial 20 min of rest with the subjects in a supine position, the extracranial arteries, i.e., the common carotid arteries, internal carotid arteries (ICA) and the vertebral arteries (VA) of both sides were explored with a 7.0 MHz linear transducer of a computed sonography system (Toshiba PowerVision 6000). The examination followed a previously described protocol [7]. CBF volume was determined as the sum of the flow volumes of the ICA and the VA of both sides. Resistance index, as a measure of cerebrovascular resistance, was calculated as follows: (peak systolic velocity end diastolic velocity)/peak systolic velocity [12].

Posted in Uncategorized | Leave a comment

In conclusion, we have

In conclusion, we have see more shown that CBF was reduced in elderly males with mild to moderate CHF, and was independently associated with factors that represent the severity of CHF. Reduced CBF was associated with impaired physical performance, and deteriorated quality of life, as well. Future studies are now needed to tease out possible association of CBF with cerebral disorders known to be more potentiated in the population with heart failure as well as to investigate the possible underlying mechanisms. “
“Radiation vasculopathy affects patients with primary brain tumor and causes significant morbidity from

ischemia related to hemodynamic insufficiency [1] and [2]. In these patients, medical management for secondary stroke prevention commonly includes HMG-CoA reductase inhibitors, or statins. Previous studies have shown that statin use improves cerebrovascular reactivity [3]. We report a contradictory finding in a unique patient with radiation vasculopathy and suggest broader implications for patients with hemodynamic insufficiency. Selleck OSI906 A 66 year old man who underwent surgery and radiation for glioblastoma multiforme presented 6 months post surgery with new onset left sided weakness. He was found with a right

middle cerebral artery infarct and placed on simvastatin along with aspirin. He underwent a baseline transcranial Doppler (TCD) and then had his statin withdrawn. He was then brought back to the clinic 6 weeks later for follow-up study. Initial TCD showed no significant stenoses by velocity criteria in the proximal vessels of the circle of Willis. Interestingly, however, there was flow diversion on the right with ACA > MCA velocity, suggesting distal stenosis. The breath holding index was 0.42. 6 weeks later, after statin withdraw, TCD showed persistent flow diversion, but significant improvement in the BHI to 0.78. The data from this patient suggests small arteriolar disease from radiation vasculopathy causing poor hemodynamic flow to the right hemisphere.

Although the precise means by which statins worsen the hemodynamic flow to the affected hemisphere is unknown, the mechanism we propose below for this finding is based on previous studies in which statins Nintedanib have been shown to improve cerebrovascular flow [3]. While these findings seem to be contradictory, the finding in radiation vasculopathy is actually a logical extension of the larger theory regarding statin effects on cerebral blood flow and in fact corroborates the other findings of flow augmentation. Statins have the effect of decreasing cholesterol synthesis, and do so by inhibiting the upstream enzyme HMG CoA reductase. The downstream effect of this inhibition is the decreased production of not only cholesterol, but also geranyl pyrophosphate, a constituent of the family of small GTPases known as Rho. In the absence of geranyl pyrophosphate, less of the Rho GTPases are active [4].

Posted in Uncategorized | Leave a comment